Form 4: Vaxcyte CFO Transfers Shares to Estate Planning Trust

Vaxcyte President and CFO Andrew Guggenhime transferred 61,850 shares of common stock to a grantor retained annuity trust (GRAT) via ALG 2025 GRAT HOLDINGS LLC.

Summary

• Andrew Guggenhime, President and CFO of Vaxcyte, Inc., reported a change in beneficial ownership of Vaxcyte common stock.
• On January 14, 2026, Guggenhime transferred 61,850 shares of Vaxcyte common stock.
• The transfer was made to ALG 2025 GRAT HOLDINGS LLC, an entity where Guggenhime serves as the sole member and manager.
• These shares are indirectly held by a grantor retained annuity trust (GRAT), for which Guggenhime is the sole annuitant and trustee.
• The transaction was executed at a price of $0 per share, indicating a transfer for estate planning purposes rather than a market sale.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, signifying it was a pre-planned arrangement.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction for personal estate planning, not indicative of company performance or significant operational changes.

Positives

• The transaction was pre-planned under a Rule 10b5-1(c) plan, demonstrating a structured approach to personal financial and estate management by a key executive.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's operations or financial performance.

Industry Context

This filing is a routine insider transaction related to personal financial planning and does not directly reflect broader industry trends or competitive dynamics. Such transfers to grantor retained annuity trusts (GRATs) are common estate planning tools for executives.

Related Party Transactions

• Andrew Guggenhime, President and CFO, transferred 61,850 shares of Vaxcyte common stock to ALG 2025 GRAT HOLDINGS LLC, an entity where he is the sole member and manager, and which holds shares for a grantor retained annuity trust (GRAT) where he is the sole annuitant and trustee. This constitutes a related party transaction for estate planning purposes.

Stakeholder Impact

• Shareholders: No direct impact on company operations or valuation, but provides transparency into insider holdings and estate planning activities.
• Employees, Customers, Suppliers, Creditors: No direct impact from this personal financial transaction.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned transfer of shares by a key executive to a grantor retained annuity trust (GRAT) for estate planning purposes. It is not a sale for cash and does not reflect a change in the executive's confidence in the company or its operational performance. As such, it provides no new information that would warrant a change in investment recommendation for Vaxcyte, Inc. Investors should continue to hold based on fundamental analysis of the company's business and prospects, rather than this specific insider transaction.

Keywords

Vaxcyte, PCVX, Form 4, Insider Transaction, Andrew Guggenhime, CFO, Grantor Retained Annuity Trust, GRAT, Stock Transfer, Beneficial Ownership, Rule 10b5-1